Medpace Holdings, Inc. (MEDP) Form 10-Q — Oct 22, 2026
Medpace reported Q3 2026 revenue of $716.0 million, up 8.5% year over year, with net income of $137.5 million and diluted EPS of $4.84 versus $3.86 a year ago. Growth was driven primarily by the Metabolic, Oncology and Central Nervous System therapeutic areas. Backlog rose 5.6% to $3,167.2 million, with net new business awards of $873.4 million in the quarter and $2,287.6 million for the nine months. The company expects roughly $1,980-$2,000 million of backlog to convert to revenue over the next twelve months.
Key figures
- Eps
- 4.84
- Revenue
- 716000000
- Net Income
- 137460000
- Revenue Yoy
- 8.5%
- Total Assets
- 2302595000
- Cash Position
- 705315000
- Shares Outstanding
- 27971686
- Q3 2025 revenue
- 659903000
- Backlog yoy growth
- 5.6%
- Nine month revenue
- 2129935000
- Q3 2025 diluted eps
- 3.86
- Effective tax rate q3
- 19.6%
- Nine month net income
- 382692000
- Nine month diluted eps
- 13.37
- Nine month revenue yoy
- 16.9%
- Net new business awards q3
- 873400000
- New repurchase authorization
- 1000000000
- Share repurchases nine month
- 294700000
- Operating cash flow nine month
- 530396000
- Remaining repurchase authorization
- 527000000
- Expected 12 month backlog conversion
- $1,980.0-$2,000.0 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.